The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer
LOS ANGELES, Calif., Nov. 11, 2019 /PRNewswire/ -- Four new Prostate Cancer Foundation (PCF) Centers of Excellence (COEs) have joined the PCF's dedicated network of centers executing the ambitious mission of improving the...Read More
THE PROSTATE CANCER FOUNDATION ANNOUNCES A COLLABORATIVE GRANTS PROGRAM IN PROSTATE CANCER RESEARCH
LOS ANGELES, Calif., September 26, 2019 – The Prostate Cancer Foundation (PCF) today announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through...Read More
FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer
September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC). Apalutamide has previously...Read More
The Prostate Cancer Foundation Made History by Lighting U.S. Landmarks “Blue” Across All 50 States to Illuminate Prostate Cancer Issue
LOS ANGELES, Calif., September 4, 2019 – For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September...Read More
The Prostate Cancer Foundation and the Movember Foundation Announce 2019 Challenge Award Winners
The Prostate Cancer Foundation (PCF) and the Movember Foundation today announced three new Movember Foundation-PCF Challenge Awards. These are granted to teams at some of the world’s leading cancer research...Read More
FDA Approves Bayer’s Nubeqa® (darolutamide), a New Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer
WHIPPANY, N.J., July 30, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today approved Nubeqa® (darolutamide), an androgen receptor inhibitor (ARi), for the treatment of patients with non-metastatic...Read More
Gene test picks out prostate cancer patients who could benefit from ‘search-and-destroy’ medicine
Original Press Release Issued by: The Institute of Cancer Research, London Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of...Read More
Newly defined cancer driver is Fast, Furious and Loud
Original Press Release Issued by: University of Michigan Medicine ANN ARBOR, Michigan — The Fast and the Furious movie franchise meets the Fast N’ Loud television series to define an...Read More
THE PROSTATE CANCER FOUNDATION AND MAJOR LEAGUE BASEBALL KICK OFF 24th ANNUAL HOME RUN CHALLENGE ON JUNE 1st
One in 9 U.S. men will be diagnosed with prostate cancer which is equivalent to at least one player on a baseball team One man dies from prostate cancer every...Read More
Black men less likely than nonblack patients to adopt active surveillance for low-risk prostate cancer
Original Press Release Issued by: Dana-Farber Cancer Institute Overall active surveillance rates are up, though the increase is significantly smaller for black patients Black men may be deterred by both socioeconomic...Read More